1. Home
  2. CCO vs URGN Comparison

CCO vs URGN Comparison

Compare CCO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clear Channel Outdoor Holdings Inc.

CCO

Clear Channel Outdoor Holdings Inc.

HOLD

Current Price

$2.40

Market Cap

1.2B

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$29.94

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCO
URGN
Founded
1995
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2005
2016

Fundamental Metrics

Financial Performance
Metric
CCO
URGN
Price
$2.40
$29.94
Analyst Decision
Hold
Strong Buy
Analyst Count
5
7
Target Price
$2.12
$29.29
AVG Volume (30 Days)
7.3M
595.6K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
110.81
N/A
EPS
N/A
N/A
Revenue
$1,604,140,000.00
$1,128,000.00
Revenue This Year
$5.35
$129.09
Revenue Next Year
$4.26
$70.96
P/E Ratio
N/A
N/A
Revenue Growth
6.57
N/A
52 Week Low
$1.00
$12.62
52 Week High
$2.43
$32.37

Technical Indicators

Market Signals
Indicator
CCO
URGN
Relative Strength Index (RSI) 49.35 61.76
Support Level $2.37 $26.67
Resistance Level $2.41 $30.34
Average True Range (ATR) 0.01 1.54
MACD -0.00 -0.06
Stochastic Oscillator 25.00 72.75

Price Performance

Historical Comparison
CCO
URGN

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: